Loading...
Market
Will GSK face new legal actions related to Zantac by December 31, 2024?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Court filings or news reports from reputable sources
Story
GSK to Pay Up to $2.2B to Settle 80,000 U.S. Zantac Contamination Cases
Oct 9, 2024, 05:05 PM
GlaxoSmithKline (GSK) announced that it has reached agreements to settle approximately 80,000 U.S. state court Zantac product liability cases, representing 93% of such cases, for up to $2.2 billion. The litigation concerns claims related to the contamination of its Zantac (ranitidine) reflux medication. The settlements, involving agreements with ten plaintiff firms, are expected to be finalized by the first half of 2025. GSK will record a charge of £1.8 billion ($2.3 billion) in its third-quarter 2024 results to cover the settlement costs. Additionally, the company resolved a Qui Tam complaint for $70 million. GSK's shares were briefly halted pending the news and have since resumed trading.
View original story
Similar markets
Less than 3 • 25%
3 to 5 • 25%
6 to 10 • 25%
More than 10 • 25%
FDA • 25%
FTC • 25%
SEC • 25%
None • 25%
Less than $2 billion • 25%
$2 billion to $2.5 billion • 25%
$2.5 billion to $3 billion • 25%
More than $3 billion • 25%
GSK wins • 25%
Plaintiff wins • 25%
Case dismissed • 25%
Settlement reached • 25%
GSK • 25%
Sanofi • 25%
Pfizer • 25%
Other • 25%
Stock price increases • 25%
Stock price decreases • 25%
Stock price remains stable • 25%
Insufficient data • 25%